BioCentury
ARTICLE | Company News

Apex Bioscience deal

September 26, 1994 7:00 AM UTC

Apex and Duke University will develop drugs that modulate nitric oxide levels to treat diseases such as shock-induced hypotension, cancer and autoimmune disorders. In return for providing $1 million in funding, Apex received an option to license Duke patents on technology that emerges from the research under the three-year agreement.

When the immune system is activated, macrophages produce nitric oxide, which helps the immune system destroy foreign bacteria and fungi. ...